TrialNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2024

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+).

James F Howard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.